Vericel Corporation is an American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Vericel is a commercial stage company with three marketed drugs. The company's research focus is on cell-based therapies. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2013, Aastrom Bio acquired from Sanofi their "cell therapy and regenerative medicine business" which it had received when purchasing Genzyme in 2011. This transformed the company in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market (which it had not had before). In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
(Summary) (Company) (Chart)
| 13 August 2017 Price $3.50 1yr Target $6.56 Analysts 4 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 87.42% Yield 0.00% 1yr Tot Return 87.42% P/E --- PEG --- Beta 3.13 | EPS (ttm) $-1.24 EPS next yr $-0.45 Forward P/E --- EPS next 5yr --- 1yr Price Support --- Market Cap $112.81 Mil Revenues $49.60 Mil Earnings $-31.50 Mil Profit Margin --- Quick Ratio 2.20 Current Ratio 2.50 Debt/Equity 0.65 | 1yr RevGR 6.28% 3yr RevGR 1,282.65% 5yr RevGR 396.63% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -85.80% ROE 238.60% |
My Perspective
This is an interesting company. It's biotechnology and it's regenerative therapies. Both of these are very interesting to me. But interesting and financial viable are two separate things. So for now, my interest will put this company on my watch list but it won't get me involved financially. So for now, I'll just keep an eye on this with the intent to start a position if and when the fundamentals and technicals become convincing. My gut feeling is that the technicals may become compelling long before the fundamentals do.
Print 
PDF
RSS Feed
